Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive biomarker for many tumors. This study aimed to investigate the potential of circulating miR-125b as a prognostic marker of HCC. Exosomes were e...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2017-01, Vol.10, p.3843-3851
Main Authors: Liu, Weifeng, Hu, Jie, Zhou, Kaiqian, Chen, Feiyu, Wang, Zheng, Liao, Boyi, Dai, Zhi, Cao, Ya, Fan, Jia, Zhou, Jian
Format: Article
Language:English
Subjects:
Biomarkers
Care and treatment
Comparative analysis
Development and progression
Gene expression
Genetic aspects
Health aspects
Hepatitis
Hepatocellular carcinoma
Hepatology
Identification
Laboratories
Liver cancer
Liver cirrhosis
Medical prognosis
Membranes
Metastasis
MicroRNA
MicroRNAs
Microscopy
NMR
Nuclear magnetic resonance
Original Research
Prognosis
Statistical analysis
Surgery
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with high mortality. Circulating miRNA has been demonstrated as a novel noninvasive biomarker for many tumors. This study aimed to investigate the potential of circulating miR-125b as a prognostic marker of HCC. Exosomes were extracted from serum samples collected from two independent cohorts: cohort 1: HCC (n=30), chronic hepatitis B (CHB, n=30), liver cirrhosis (LC, n=30); cohort 2: HCC (n=128). We found that miR-125b levels were remarkably increased in exosomes compared to those in serum from patients with CHB, LC, and HCC (
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S140062